We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





LumiraDx Presents Its Next-Generation POC Diagnostics Platform and Fast Lab Solutions at MEDLAB Middle East

By Carolyn Moody, RN - News Editor
Posted on 25 Jan 2022
Print article
Image: LumiraDx at MEDLAB Middle East (Photo courtesy of LumiraDx)
Image: LumiraDx at MEDLAB Middle East (Photo courtesy of LumiraDx)

LumiraDx (London, UK) presented its next-generation point of care diagnostics platform which provides a broad menu of lab comparable results on a single, portable diagnostic platform at MEDLAB Middle East 2022. LumiraDx also highlighted its Fast Lab Solutions which enable laboratories to improve throughput by using current molecular infrastructure and eliminating the need for extraction and purification.

The 21st MedLab Middle East took place in Dubai and was once again be co-located with Arab Health, bringing together an international audience of almost 4,000 exhibitors from the healthcare and laboratory industries from nearly 160 countries and more than 60,000 attendees across the four days. MedLab Middle East showcases the future of medical technology to the healthcare and laboratory communities. This year’s event allowed delegates to network with industry peers, meet, explore the latest products and attend educational sessions. Alongside the exhibition, MedLab Middle East runs the region's only multi-disciplinary congress with eight CME accredited tracks covering topics such as Laboratory management and molecular diagnostics.

LumiraDx exhibited for the first time in-person at MedLab Middle East where its team demonstrated its transformative tests and technology alongside its Fast Lab Solutions. LumiraDx demonstrated its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions for use on the LumiraDx Platform, including its LumiraDx SARS-CoV-2 Ag Test, LumiraDx SARS-CoV-2 Ag Pool Test and LumiraDx SARS-CoV-2 Ab Test. The company also presented Fast Lab Solutions, a dedicated LumiraDx business unit that supports high-complexity laboratory testing by utilizing its innovative qSTAR (Selective Temperature Amplification Reaction) nucleic acid amplification technology in an accessible high-throughput format to leverage current molecular laboratory operations. qSTAR is transforming molecular diagnostics by providing fast, accurate, and high throughput testing solutions with rapid amplification within 20 minutes or less on open RT-PCR instrumentation. Utilizing FastLab Solutions enables laboratories to improve efficiency and reduce time to result.

Related Links:
LumiraDx 

Gold Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
New
Gold Supplier
Chemistry Analyzer
BS-600M
New
Microplate Reader
VANTAstar
New
3-DIFF Hematology Analyzer
MYTHIC 18

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.